The integrity of the FDA’s advisory process faces a severe stress test following the Circulatory System Devices Panel’s review of Abbott’s TriClip G4 System. On February 13, 2024, the panel voted 13-1 that the benefits of the device outweighed its risks. Abbott’s stock and market position benefited immediately from this near-unanimous endorsement. A subsequent investigation by KFF Health News in April 2024 shattered the illusion of impartial consensus. Open Payments data revealed that 10 of the 14 voting members had accepted payments from Abbott Laboratories totaling approximately $650,000 between 2016 and 2022.

These financial ties were not disclosed to the public during the broadcasted meeting. The FDA’s conflict of interest screening failed to flag these sums as disqualifying. The agency operates under a "direct matter" standard. This rule allows advisors to accept general consulting fees, travel compensations, and research grants from a company as long as the payments are not specifically earmarked for the device under review. The result is a regulatory blind spot where decision-makers collect six-figure sums from the very entities they regulate.